Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income of -$24.15M in Q2 FY2026
Q2 FY2026 net income was -$24.15M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (63.91M) USD
- Year-over-year change
- —
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (63.91M) | — |
Net Income vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's FY2025 net income of $63.91M is the 3rd largest of the 5 companies compared; the peer median is $117.15M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IRONDisc Medicine, Inc. | LTM Sep 2026 | $243.1M | +34.2% | +65.5% | — |
| LTM Mar 2026 | $208.87M | -4.0% | +16.2% | 1154.4% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $63.91M | — | — | — |
DMRADamora Therapeutics, Inc. | LTM Jun 2024 | $25.43M | — | +50.4% | — |
| LTM Mar 2026 | $7.82M | -83.8% | -48.7% | 911.1% | |
| Peer median (excluding COAG) | $117.15M | -4.0% | +33.3% | 1032.7% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (63.91M) |
| Depreciation & Amortization | 304K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.01M |
| Change in Working Capital | 1.36M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 2.58M |
| Other Working Capital | (1.22M) |
| Other Non-Cash Items | (1.23M) |
| Operating Cash Flow | (61.48M) |
| Capital Expenditures | (16K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (252.5M) |
| Sales of Investments | 171.03M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (81.48M) |
| Debt Repayment | (120K) |
| Common Stock Issued | 0 |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | 0 |
| Financing Cash Flow | 156.3M |
| Effect of Forex Changes | 223K |
| Net Change in Cash | 13.57M |
| Free Cash Flow | (61.49M) |
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.